Health care stocks were leaning lower premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was down 0.7% and the iShares Biotechnology ETF (IBB) was inactive.
Marinus Pharmaceuticals (MRNS) soared 43% after it said it signed a deal under which Immedica Pharma will acquire all of its issued and outstanding shares for $0.55 a share.
Axsome Therapeutics (AXSM) said Monday it has met the primary endpoint in its ACCORD-2 phase 3 trial of AXS-05, which is intended for Alzheimer's disease agitation, but failed to achieve statistical significance for its primary endpoint in another trial. Axsome shares slid 7.1%.
Precigen (PGEN) said Monday it has completed a rolling biologics license application submission to the US Food and Drug Administration for PRGN-2012, a treatment for recurrent respiratory papillomatosis in adults. Precigen shares rose 12.8%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.